Cargando…
Ketorolac modulates Rac-1/HIF-1α/DDX3/β-catenin signalling via a tumor suppressor prostate apoptosis response-4 (Par-4) in renal cell carcinoma
Renal cell carcinoma (RCC) is the most difficult-to-treat form of kidney cancer with a median 5-year survival of 10% under metastatic setting. In RCC, although cytoreductive nephrectomy is common, approximately 20–30% of patients will develop recurrent cancer after surgery, which highlights the need...
Autores principales: | Sonawane, Vinay, Ghosalkar, Jeevan, Achrekar, Swati, Joshi, Kalpana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079967/ https://www.ncbi.nlm.nih.gov/pubmed/37024613 http://dx.doi.org/10.1038/s41598-023-32627-z |
Ejemplares similares
-
Prostate Apoptosis Response-4 (Par-4): A Novel Target in Pyronaridine-Induced Apoptosis in Glioblastoma (GBM) Cells
por: Ghosalkar, Jeevan, et al.
Publicado: (2022) -
Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer
por: Samal, Sabindra K., et al.
Publicado: (2015) -
Tumor Suppressor Par-4 Regulates Complement Factor C3 and Obesity
por: Araujo, Nathalia, et al.
Publicado: (2022) -
HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner
por: Turgu, Busra, et al.
Publicado: (2021) -
Structural Analysis of the cl-Par-4 Tumor Suppressor as a Function of Ionic Environment
por: Raut, Krishna K., et al.
Publicado: (2021)